Dr. Reddy’s Laboratories launches Tobramycin Inhalation Solution, USP in the U.S. market
Dr. Reddy’s is launching Tobramycin Inhalation Solution, USP a therapeutic equivalent generic version of TOBI
Pharmaceuticals, Biotechnology and Life Sciences
Dr. Reddy’s is launching Tobramycin Inhalation Solution, USP a therapeutic equivalent generic version of TOBI
It is approved for the treatment of type 2 diabetes and currently in Phase III trials for the treatment of type 1 diabetes, as well as for chronic kidney disease including diabetic nephropathy.
Keytruda’s market potential in this indication remains limited due to its approval for primary mediastinal B-cell lymphoma (PMBCL), which only accounts for a small percentage of non-Hodgkin’s lymphoma (NHL) patients.
Tilray has imported medical cannabis oral solutions in bulk into the United Kingdom from its Good Manufacturing Practices (GMP)-certified facility in Canada.
Amring Pharmaceuticals, a generic pharmaceutical and ophthalmic medical device company, announced today that it has launched two valued drugs into its generic portfolio and to the U.S. Market.
Imeglimin in combination with insulin Phase 3 TIMES 3 16-week, double-blind, placebo-controlled, randomized part of the trial met its primary endpoint with a favorable safety and tolerability profile
FDA has approved Ipsen’s new pre-filled syringe for Somatuline
Depot.
Dermira set to receive an option exercise fee of $50 million and additional potential milestone payments and royalties
Longboat Clinical, the clinical technology company specializing in site and patient engagement platforms, today announced the release of Patient CONNECT, a unique solution to streamline patient recruitment into clinical trials and provide much sought-after insights to drug development teams.
DUBLIN–(BUSINESS WIRE)–The “Inhalers – Medical Devices Pipeline Assessment, 2019” report has been added to ResearchAndMarkets.com’s offering. The Medical Devices sector…